These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 16490578

  • 1. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Schiller DS.
    Clin Ther; 2006 Jan; 28(1):36-44. PubMed ID: 16490578
    [Abstract] [Full Text] [Related]

  • 2. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupDepartment of Ophthalmology, Harvard Medical School, Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. djdamico@meei.harvard.edu, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B.
    Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
    [Abstract] [Full Text] [Related]

  • 3. Pegaptanib for neovascular age-related macular degeneration.
    Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group.
    N Engl J Med; 2004 Dec 30; 351(27):2805-16. PubMed ID: 15625332
    [Abstract] [Full Text] [Related]

  • 4. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Abrams P.
    Clin Ther; 2007 Sep 30; 29(9):1850-61. PubMed ID: 18035187
    [Abstract] [Full Text] [Related]

  • 5. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
    VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupCentre for Vision Sciences, The Queen's University of Belfast and The Royal Victoria Hospital, Belfast, United Kingdom., Chakravarthy U, Adamis AP, Cunningham ET, Goldbaum M, Guyer DR, Katz B, Patel M.
    Ophthalmology; 2006 Sep 30; 113(9):1508.e1-25. PubMed ID: 16828500
    [Abstract] [Full Text] [Related]

  • 6. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
    Macugen AMD Study GroupDepartment of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri 63110, USA., Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP.
    Ophthalmology; 2007 Sep 30; 114(9):1702-12. PubMed ID: 17509689
    [Abstract] [Full Text] [Related]

  • 7. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
    Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.
    Health Technol Assess; 2008 May 30; 12(16):iii-iv, ix-201. PubMed ID: 18462575
    [Abstract] [Full Text] [Related]

  • 8. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
    Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W, ABC Trial Investigators.
    BMJ; 2010 Jun 09; 340():c2459. PubMed ID: 20538634
    [Abstract] [Full Text] [Related]

  • 9. Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.
    Doggrell SA.
    Expert Opin Pharmacother; 2005 Jul 09; 6(8):1421-3. PubMed ID: 16013991
    [Abstract] [Full Text] [Related]

  • 10. [Long-term efficacy and safety profile of pegaptanib sodium for age-related macular degeneration with choroidal neovascularization--evaluation of extended phase II clinical trial].
    Pegaptanib Sodium Multi-center Study Group.
    Nippon Ganka Gakkai Zasshi; 2011 Feb 09; 115(2):122-33. PubMed ID: 21400918
    [Abstract] [Full Text] [Related]

  • 11. [Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration].
    Tano Y, Pegaptanib Sodium Multi-center Study Group.
    Nippon Ganka Gakkai Zasshi; 2008 Jul 09; 112(7):590-600. PubMed ID: 18702350
    [Abstract] [Full Text] [Related]

  • 12. Pegaptanib for neovascular age-related macular degeneration.
    Maberley D.
    Issues Emerg Health Technol; 2005 Dec 09; (76):1-4. PubMed ID: 16544440
    [Abstract] [Full Text] [Related]

  • 13. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience.
    Sivaprasad S, Hykin P, Saeed A, Beatty S, Grisanti S, Staurenghi G, Olea JL, Campos A, Barbosa A, Rito L, Silva R, Faria R, Eldem B, Kadayifçilar S, Kolar P, Feucht N, Maestroni L.
    Eye (Lond); 2010 May 09; 24(5):793-8. PubMed ID: 19786957
    [Abstract] [Full Text] [Related]

  • 14. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
    Quiram PA, Hassan TS, Williams GA.
    Retina; 2007 Sep 09; 27(7):851-6. PubMed ID: 17891008
    [Abstract] [Full Text] [Related]

  • 15. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S, Kaplowitz K, Brubaker JW, Updike PG, Collins AT, Walsh AC, Romano PW, Sadda SR.
    Ophthalmology; 2008 Feb 09; 115(2):347-354.e2. PubMed ID: 17628685
    [Abstract] [Full Text] [Related]

  • 16. Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series.
    Atmani K, Coscas F, Coscas G, Soubrane G.
    Eye (Lond); 2009 May 09; 23(5):1150-4. PubMed ID: 18636083
    [Abstract] [Full Text] [Related]

  • 17. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
    Maier M, Feucht N, Huebner M, Lohmann C.
    Klin Monbl Augenheilkd; 2008 Jun 09; 225(6):582-7. PubMed ID: 18516780
    [Abstract] [Full Text] [Related]

  • 18. Pegaptanib: in exudative age-related macular degeneration.
    Siddiqui MA, Keating GM.
    Drugs; 2005 Jun 09; 65(11):1571-7; discussion 1578-9. PubMed ID: 16033295
    [Abstract] [Full Text] [Related]

  • 19. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis.
    Gonzales CR, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group.
    Retina; 2005 Jun 09; 25(7):815-27. PubMed ID: 16205558
    [Abstract] [Full Text] [Related]

  • 20. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
    Takeda AL, Colquitt J, Clegg AJ, Jones J.
    Br J Ophthalmol; 2007 Sep 09; 91(9):1177-82. PubMed ID: 17475698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.